Preeclampsia and risk of developing subsequent diabetes preeclampsia and risk of subsequent diabetes

Hypertension in Pregnancy

Volumn 28, Issue 4, 2009, Pages 435-447

  Carr, D B ^a   Newton, K M ^b,c   Utzschneider, K M ^c   Tong, J ^c   Gerchman, F ^c   Kahn, S E ^c   Easterling, T R ^a   Heckbert, S R ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Diabetes; Epidemiology.; Gestational diabetes; Preeclampsia

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; GLUCOSE; INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; REPAGLINIDE; SULFONYLUREA;

ADULT; ARTICLE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; RETROSPECTIVE STUDY; RISK ASSESSMENT;

AGE FACTORS; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; FEMALE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; PRE-ECLAMPSIA; PREGNANCY; RETROSPECTIVE STUDIES; RISK;

EID: 70350322131     PISSN: 10641955     EISSN: 15256065     Source Type: Journal    
DOI: 10.3109/10641950802629675     Document Type: Article

References (53)

1. Hauth JC, Ewell MG, Levine RJ, Esterlitz JR, Sibai B, Curet LB, et al. Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group. Obstet Gynecol 2000 Jan; 95(1):24-28.
2. Cunningham FG, Gant NF, Leveno KJ, Gilstrap LCI, Hauth JC, Wenstrom KD. Hypertensive disorders in pregnancy. Williams Obstetrics. 21st Edition ed. New York: McGraw-Hill; 2001. p. 567-618.
3. D'Anna R, Baviera G, Corrado F, Giordano D, De Vivo A, Nicocia G, et al. Adiponectin and insulin resistance in early- and late-onset pre-eclampsia. BJOG 2006 Nov; 113(11):1264-1269.
4. Kaaja R, Laivuori H, Laakso M, Tikkanen MJ, Ylikorkala O. Evidence of a state of increased insulin resistance in preeclampsia. Metabolism 1999; 48:892-896.
5. Emery SP, Levine RJ, Qian C, Ewell MG, England LJ, Yu KF, et al. Twentyfour- hour urine insulin as a measure of hyperinsulinaemia/insulin resistance before onset of pre-eclampsia and gestational hypertension. Bjog 2005 Nov; 112(11):1479-1485.
6. Parretti E, Lapolla A, Dalfra M, Pacini G, Mari A, Cioni R, et al. Preeclampsia in lean normotensive normotolerant pregnant women can be predicted by simple insulin sensitivity indexes. Hypertension 2006 Mar; 47(3):449-453.
7. Hubel CA, McLaughlin MK, Evans RW, Hauth BA, Sims CJ, Roberts JM. Fasting serum triglycerides, free fatty acids, and malondialdehyde are increased in preeclampsia, are positively correlated, and decrease with 48 hours post partum. Am J Obstet Gynecol 1996; 174:975-982.
8. Sacks G, Studena K, Sargent I, Redman C. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998; 179:80-86.
9. Williams MA, Farrand A, Mittendorf R, Sorensen TK, Zingheim RW, O'Reilly GC, et al. Maternal second trimester serum tumor necrosis factor-a soluble receptor p55 (sTNFp55) and subsequent risk of preeclampsia. Am J Epidemiol 1999; 149:323-329.
10. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004 Feb 12; 350(7):672-683.
11. Bosio P, O'Herlihy R, Conroy P, McKenna P. Maternal central hemodynamics in hypertensive disorders of pregnancy: a longitudinal study. Am J Obstet Gynecol 1998; 178:S6.
12. Easterling T, Benedetti T, Schmucker B, Millard S. Maternal hemodynamics in normal and preeclamptic pregnancies: A longitudinal study. Obstet Gynecol 1990; 76:1061-1069.
13. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 Oct 25; 112(17):2735-2752.
14. Wolf M, Hubel CA, Lam C, Sampson M, Ecker JL, Ness RB, et al. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab 2004 Dec; 89(12):6239-6243.
15. Laivuori H, Tikkanen MJ, Ylikorkala O. Hyperinsulinemia 17 years after preeclamptic first pregnancy. J Clin Endocrinol Metab 1996; 81:2908-2911.
16. Forest JC, Girouard J, Masse J, Moutquin JM, Kharfi A, Ness RB, et al. Early occurrence of metabolic syndrome after hypertension in pregnancy. Obstet Gynecol 2005 Jun; 105(6):1373-1380.
17. Fuh M, Yin C, Pei D, Sheu W, Jeng C, Ida Chen Y, et al. Resistance to insulinmediated glucose uptake and hyperinsulinemia in women who had preeclampsia during pregnancy. Am J Hypertens 1995; 8:768-771.
18. Chesley L, Annitto J, Cosgrove R. The remote prognosis of eclamptic women. Am J Obstet Gynecol 1976; 124:446-459.
19. Bryans CI, Jr. The remote prognosis in toxemia of pregnancy. Clin Obstet Gynecol 1966 Dec; 9(4):973-990.
20. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001; 28:1607-1612.
21. Adams E, MacGillivray I. Long-term effect of pre-eclampsia on blood-pressure. Lancet 1961; 32:1373-1375.
22. Sibai B, El-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol 1986; 155:1011-1016.
23. Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003 Apr 19;326(7394):845.
24. Jonsdottir L, Arngrimsson R, Geirsson R, Sigvaldason H, Sigfusson N. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Acta Obstet Gynecol Scand 1995; 74:772-776.
25. Hannaford P, Ferry S, Hirsch S. Cardiovascular sequalae of toxaemia of pregnancy. Heart 1997; 77:154-158.
26. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 2001 Jun 23; 357(9273):2002-2006.
27. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. Bmj 2001 Nov 24; 323(7323):1213-1217.
28. Kestenbaum B, Seliger SL, Easterling TR, Gillen DL, Critchlow CW, Stehman- Breen CO, et al. Cardiovascular and thromboembolic events following hypertensive pregnancy. Am J Kidney Dis 2003 Nov; 42(5):982-989.
29. Funai EF, Friedlander Y, Paltiel O, Tiram E, Xue X, Deutsch L, et al. Long-term mortality after preeclampsia. Epidemiology 2005 Mar; 16(2):206-215.
30. Libby G, Murphy DJ, McEwan NF, Greene SA, Forsyth JS, Chien PW, et al. Pre-eclampsia and the later development of type 2 diabetes in mothers and their children: an intergenerational study from the Walker cohort. Diabetologia 2007 Mar; 50(3):523-530.
31. Callaway LK, Lawlor DA, O'Callaghan M, Williams GM, Najman JM, McIntyre HD. Diabetes mellitus in the 21 years after a pregnancy that was complicated by hypertension: findings from a prospective cohort study. Amer J Obstetrics Gynecol 2007 Nov;197(5):492 e1-7.
32. Joffe GM, Esterlitz JR, Levine RJ, Clemens JD, Ewell MG, Sibai BM, et al. The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol 1998 Oct; 179(4):1032-1037.
33. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes. Diabetes Care 2002; 25:1862-1868.
34. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004; 27 (Suppl 1):S11-14.
35. Newton KM, La Croix AZ, Heckbert SR, Abraham L, McCulloch D, Barlow W. Estrogen therapy and risk of cardiovascular events among women wtih type 2 diabetes. Diabetes Care 2003; 26:2810-2816.
36. Stone JL, Lockwood CJ, Berkowitz GS, Alvarez M, Lapinski R, Berkowitz RL. Risk factors for severe preeclampsia. Obstet Gynecol 1994 Mar; 83(3):357-361.
37. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004 Aug; 53(8):2087-2094.
38. Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ, Newell-Morris L, Kahn SE, et al. Visceral adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese Americans. Diabetes Care 2003; 26:650-655.
39. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care 2000; 23:465-471.
40. Fujimoto WY, Bergstrom RW, Boyko EJ, Chen KW, Leonetti DL, Newell-Morris L, et al. Visceral adiposity and incident coronary heart disease in Japanese-American men. The 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study. Diabetes Care 1999; 22:1808-1812.
41. van Harmelen V, Dicker A, Ryden M, Hauner H, Lonnqvist F, Naslund E, et al. Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes 2002; 51:2029-2036.
42. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46:459-469.
43. Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, et al. Serum levels of tumor necrosis factor-a are increased in obese patients with noninsulindependent diabetes mellitus. J Clin Endocrinol Metab 1998; 83:859-862.
44. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46:860-867.
45. Reith A, Booth N, Moore N, Cruickshank D, Bennett B. Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, preeclampsia, and hydatidiform mole. Br J Obstet Gynaecol 1993; 100:370-374.
46. Kenny SJ, Aubert R, Geiss LS. Prevalence and incidence of non-insulin dependent diabetes. Diabetes in America. 2nd ed: NIH NIDDK; 1995. p. 47-67.
47. Lydon-Rochelle MT, Holt VL, Cardenas V, Nelson JC, Easterling TR, Gardella C, et al. The reporting of pre-existing maternal medical conditions and complications of pregnancy on birth certificates and in hospital discharge data. Am J Obstet Gynecol 2005 Jul; 193(1):125-134.
48. Frederick IO, Rudra CB, Miller RS, Foster JC, Williams MA. Adult weight change, weight cycling, and prepregnancy obesity in relation to risk of preeclampsia. Epidemiology 2006 Jul; 17(4):428-434.
49. Ness RB, Markovic N, Bass D, Harger G, Roberts JM. Family history of hypertension, heart disease, and stroke among women who develop hypertension in pregnancy. Obstet Gynecol 2003 Dec; 102(6):1366-1371.
50. Qiu C, Williams MA, Leisenring WM, Sorensen TK, Frederick IO, Dempsey JC, et al. Family history of hypertension and type 2 diabetes in relation to preeclampsia risk. Hypertension 2003 Mar; 41(3):408-413. (Pubitemid 36314609)
51. Chiasson JL. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract 2006 Jan-Feb; 12 Suppl 1:25-30.
52. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006 Sep 23; 368(9541):1096-1105.
53. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.